Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Isofol Medical AB ( (SE:ISOFOL) ) has issued an update.
Isofol Medical AB has increased its total number of shares and votes to 320,491,623 following the recent exercise of series TO1 warrants, including a top guarantee commitment. The issuance, registered with the Swedish Companies Registration Office in April, adds 39,384,399 new shares and votes, modestly diluting existing ownership while strengthening the company’s capital base as it advances its oncology pipeline.
More about Isofol Medical AB
Isofol Medical AB is a clinical-stage biotechnology company based in Gothenburg, Sweden, focused on improving outcomes for patients with severe forms of cancer. Its lead drug candidate, arfolitixorin, is a next-generation folate treatment intended to boost the efficacy of standard therapies for solid tumors and is currently in phase Ib/II trials for colorectal cancer, the world’s third most common cancer.
Average Trading Volume: 1,686,261
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK214.7M
See more insights into ISOFOL stock on TipRanks’ Stock Analysis page.